Cetirizine Allergy side effects: what 30,102 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Cetirizine Hydrochloride Allergy (Cetirizine Hydrochloride)
Who reports
30,102 reports · 78% serious · 4,853 with death outcome · 79% female
Used for
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,184 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Swollen joint count increased | 1,972 | 1,222.5 1,136.8–1,314.8ROR 1,308.2 · calibrated p 1e-18 ✓ | 438.3 EB05 422.3 · IC025 +8.6 3/3 methods agree | Lab value / disease marker | serious n=1,971 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Monocyte chemotactic protein-1 increased | 22 | 1,161.4 585.1–2,305.3ROR 1,162.2 · calibrated p 5e-15 ✓ | 314.0 EB05 218.6 · IC025 +4.6 3/3 methods agree | Lab value / disease marker | serious n=22 · ♀ 0% (drug 79%) | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 399 | 1,053.2 901.2–1,230.7ROR 1,067.3 · calibrated p 2e-17 ✓ | 408.0 EB05 375.4 · IC025 +7.9 3/3 methods agree | Lab value / disease marker | serious n=399 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody positive | 4,174 | 1,008.3 962.7–1,056.1ROR 1,170.4 · calibrated p 4e-18 ✓ | 408.2 EB05 397.9 · IC025 +8.6 3/3 methods agree | Lab value / disease marker | serious PRR 302.2 · ♀ 100% (drug 79%) · 93% clinician | not reported in cached trials |
| Rheumatic fever | 2,557 | 999.9 942.0–1,061.4ROR 1,092.6 · calibrated p 9e-18 ✓ | 406.3 EB05 393.3 · IC025 +8.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=2,556 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Hepatic enzyme | 81 | 975.2 695.1–1,368.3ROR 977.9 · calibrated p 2e-16 ✓ | 368.2 EB05 305.7 · IC025 +6.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=81 · ♀ 100% (drug 79%) · 100% clinician | not reported in cached trials |
| Pemphigus | 6,940 | 893.6 863.8–924.4ROR 1,161.0 · calibrated p 4e-18 ✓ | 388.3 EB05 380.7 · IC025 +8.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 287.3 · ♀ 100% (drug 79%) · 90% clinician | not reported in cached trials |
| Deep vein thrombosis postoperative | 1,094 | 891.7 815.6–974.8ROR 925.3 · calibrated p 7e-17 ✓ | 385.7 EB05 366.9 · IC025 +8.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1,094 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Lupus vulgaris | 654 | 861.5 768.2–966.0ROR 880.6 · calibrated p 1e-16 ✓ | 378.3 EB05 354.6 · IC025 +8.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=654 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Rheumatoid factor positive | 3,007 | 767.7 729.7–807.7ROR 852.8 · calibrated p 2e-16 ✓ | 362.1 EB05 351.3 · IC025 +8.4 3/3 methods agree | Lab value / disease marker | serious n=3,005 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Grip strength | 115 | 692.3 534.4–896.8ROR 695.0 · calibrated p 4e-15 ✓ | 326.4 EB05 279.3 · IC025 +6.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=115 · ♀ 100% (drug 79%) · 100% clinician | not reported in cached trials |
| Swollen joint count | 122 | 692.0 538.2–889.6ROR 694.8 · calibrated p 4e-15 ✓ | 327.3 EB05 281.4 · IC025 +6.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=122 · ♀ 100% (drug 79%) · 100% clinician | not reported in cached trials |
| C-reactive protein | 449 | 689.4 605.0–785.4ROR 699.8 · calibrated p 2e-15 ✓ | 339.4 EB05 313.9 · IC025 +7.8 3/3 methods agree | Lab value / disease marker | serious n=449 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Duodenal ulcer perforation | 3,612 | 682.1 652.3–713.3ROR 775.0 · calibrated p 5e-16 ✓ | 342.0 EB05 332.7 · IC025 +8.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 252.1 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Cardiospasm | 258 | 604.3 511.4–714.1ROR 609.5 · calibrated p 1e-14 ✓ | 314.3 EB05 283.4 · IC025 +7.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=258 · ♀ 54% (drug 79%) | not reported in cached trials |
| Adjustment disorder with depressed mood | 871 | 534.2 489.3–583.2ROR 550.1 · calibrated p 2e-14 ✓ | 298.8 EB05 282.5 · IC025 +7.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=870 · ♀ 100% (drug 79%) · 96% clinician | not reported in cached trials |
| Hand deformity | 5,567 | 520.1 503.2–537.5ROR 637.8 · calibrated p 4e-15 ✓ | 296.0 EB05 289.5 · IC025 +8.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 237.4 · ♀ 100% (drug 79%) · 93% clinician | not reported in cached trials |
| Immunisation | 173 | 465.6 384.0–564.6ROR 468.3 · calibrated p 2e-13 ✓ | 269.5 EB05 237.5 · IC025 +7.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=173 | not reported in cached trials |
| Facet joint syndrome | 1,253 | 462.6 431.0–496.5ROR 482.6 · calibrated p 9e-14 ✓ | 275.6 EB05 263.0 · IC025 +7.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1,253 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Dislocation of vertebra | 859 | 440.9 405.0–480.0ROR 453.8 · calibrated p 2e-13 ✓ | 267.2 EB05 252.6 · IC025 +7.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=859 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| X-ray abnormal | 666 | 417.0 379.0–458.9ROR 426.4 · calibrated p 3e-13 ✓ | 257.9 EB05 241.8 · IC025 +7.6 3/3 methods agree | Lab value / disease marker | serious n=666 · ♀ 100% (drug 79%) · 97% clinician | not reported in cached trials |
| Anticipatory anxiety | 98 | 398.0 310.4–510.3ROR 399.3 · calibrated p 1e-12 ✓ | 240.5 EB05 203.1 · IC025 +6.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=98 · ♀ 100% (drug 79%) | not reported in cached trials |
| Palmoplantar keratoderma | 252 | 376.8 323.2–439.2ROR 380.0 · calibrated p 1e-12 ✓ | 239.2 EB05 215.4 · IC025 +7.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=252 · ♀ 55% (drug 79%) | not reported in cached trials |
| Helicobacter infection | 3,561 | 375.9 361.4–391.0ROR 426.2 · calibrated p 3e-13 ✓ | 242.9 EB05 236.3 · IC025 +7.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 189.3 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Subcutaneous drug absorption impaired | 184 | 356.7 298.6–426.1ROR 358.9 · calibrated p 2e-12 ✓ | 229.5 EB05 203.0 · IC025 +6.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=184 · ♀ 100% (drug 79%) · 100% clinician | not reported in cached trials |
| Retinitis | 559 | 352.3 318.3–389.9ROR 358.9 · calibrated p 2e-12 ✓ | 231.3 EB05 215.6 · IC025 +7.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=559 · ♀ 100% (drug 79%) · 96% clinician | not reported in cached trials |
| Pericarditis | 4,875 | 289.1 280.1–298.4ROR 344.8 · calibrated p 2e-12 ✓ | 203.6 EB05 198.8 · IC025 +7.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 151.3 · 91% clinician | not reported in cached trials |
| Muscle injury | 2,389 | 287.0 274.0–300.7ROR 311.7 · calibrated p 7e-12 ✓ | 202.4 EB05 195.6 · IC025 +7.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 161.7 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, insomnia type | 1,864 | 284.8 270.2–300.3ROR 303.6 · calibrated p 9e-12 ✓ | 201.2 EB05 193.6 · IC025 +7.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1,862 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Sleep disorder due to general medical condition, hypersomnia type | 29 | 284.3 184.5–438.2ROR 284.6 · calibrated p 1e-10 ✓ | 177.9 EB05 129.9 · IC025 +4.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=29 · ♀ 100% (drug 79%) · 100% clinician | not reported in cached trials |
| Vaginal flatulence | 88 | 282.2 220.2–361.6ROR 283.0 · calibrated p 3e-11 ✓ | 192.0 EB05 160.6 · IC025 +6.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=88 · ♀ 100% (drug 79%) | not reported in cached trials |
| Glossodynia (burning tongue/mouth pain) | 6,419 | 281.6 274.1–289.2ROR 357.6 · calibrated p 2e-12 ✓ | 199.8 EB05 195.8 · IC025 +7.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 213.2 · ♀ 100% (drug 79%) · 92% clinician | not reported in cached trials |
| Folliculitis | 2,741 | 252.4 241.9–263.3ROR 277.5 · calibrated p 2e-11 ✓ | 184.5 EB05 178.8 · IC025 +7.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 160.0 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Synovitis | 4,750 | 249.6 241.9–257.5ROR 296.1 · calibrated p 1e-11 ✓ | 183.1 EB05 178.8 · IC025 +7.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 141.3 · ♀ 100% (drug 79%) · 93% clinician | not reported in cached trials |
| Tender joint count | 21 | 228.8 139.6–374.8ROR 228.9 · calibrated p 1e-9 ✓ | 148.8 EB05 102.7 · IC025 +4.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=21 · ♀ 100% (drug 79%) | not reported in cached trials |
| Peripheral venous disease | 985 | 228.6 212.9–245.5ROR 236.3 · calibrated p 9e-11 ✓ | 171.2 EB05 162.4 · IC025 +7.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=984 · ♀ 100% (drug 79%) · 95% clinician | not reported in cached trials |
| Seronegative arthritis | 268 | 219.0 190.9–251.1ROR 220.9 · calibrated p 2e-10 ✓ | 164.3 EB05 148.4 · IC025 +6.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=268 · ♀ 100% (drug 79%) · 94% clinician | not reported in cached trials |
| Urticaria thermal | 34 | 216.1 147.0–317.6ROR 216.3 · calibrated p 8e-10 ✓ | 150.8 EB05 112.8 · IC025 +5.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=34 · ♀ 100% (drug 79%) | not reported in cached trials |
| Alpha tumour necrosis factor increased | 22 | 212.7 131.8–343.0ROR 212.8 · calibrated p 2e-9 ✓ | 142.7 EB05 99.3 · IC025 +4.4 3/3 methods agree | Lab value / disease marker | serious n=22 · ♀ 0% (drug 79%) | not reported in cached trials |
| Bronchial neoplasm | 30 | 196.1 130.7–294.2ROR 196.3 · calibrated p 2e-9 ✓ | 139.4 EB05 102.3 · IC025 +4.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=30 · ♀ 100% (drug 79%) | not reported in cached trials |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Liver injury | 6,554 | 15.415.1–15.8 | signal |
| Interstitial lung disease | 1,259 | 9.38.8–9.8 | signal |
| Hyperglycaemia / diabetes | 3,409 | 6.96.7–7.1 | signal |
| Anaphylaxis / angioedema | 1,151 | 6.46.1–6.8 | signal |
| Depression | 1,839 | 4.64.4–4.8 | signal |
| Serious infection | 4,848 | 4.44.3–4.5 | signal |
| Pancreatitis | 310 | 2.72.4–3.0 | signal |
| Thrombocytopenia | 677 | 2.12.0–2.3 | raised |
| Rhabdomyolysis / myopathy | 231 | 2.01.7–2.3 | raised |
| Severe cutaneous reaction | 189 | 1.81.5–2.0 | raised |
| Gi bleeding | 455 | 1.71.6–1.9 | raised |
| Opportunistic infection | 339 | 1.71.6–1.9 | raised |
| Fall / fracture | 922 | 1.71.6–1.8 | raised |
| Arrhythmia / qt | 422 | 1.51.4–1.7 | raised |
| Tendon disorder | 77 | 1.41.1–1.8 | raised |
| Hyponatraemia | 151 | 1.31.1–1.5 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Cetirizine Allergy as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).
- NCT00291642 — A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhiniti (N=551, PHASE2; 34 AE terms posted; arms: Placebo (PBO); Levocetirizine (LCTZ) 2.5 mg; Levocetirizine (LCTZ) 5 mg; Cetirizine (CTZ) 5 mg)
- NCT04189588 — Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (N=34, PHASE2; 1 AE terms posted; arms: Cohort A; Cohort B)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 9,399 | 5.0 4.9–5.1ROR 6.8 · calibrated p 0.106 | 5.0 EB05 4.9 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 4.7 · serious PRR 8.9 | not reported in cached trials |
| Pain | 8,846 | 10.1 10.0–10.3ROR 14.0 · calibrated p 0.009 ✓ | 10.0 EB05 9.8 · IC025 +3.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 8.5 · serious PRR 11.5 | NCT00291642: 1/119 (0.8%) on Cetirizine Allergy |
| Fatigue (tiredness) | 8,749 | 7.9 7.8–8.1ROR 10.8 · calibrated p 0.025 ✓ | 7.8 EB05 7.7 · IC025 +2.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 6.6 · serious PRR 10.6 | NCT00291642: 1/119 (0.8%) on Cetirizine Allergy |
| Alopecia (hair loss) | 7,448 | 27.4 26.8–27.9ROR 36.0 · calibrated p 9e-5 ✓ | 26.4 EB05 25.9 · IC025 +4.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 19.5 · serious PRR 41.3 | not reported in cached trials |
| Rheumatoid arthritis | 7,360 | 48.5 47.5–49.5ROR 63.8 · calibrated p 3e-6 ✓ | 45.3 EB05 44.5 · IC025 +5.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 35.0 · serious PRR 40.8 · ♀ 100% (drug 79%) | not reported in cached trials |
| Abdominal discomfort | 7,329 | 31.9 31.3–32.6ROR 41.9 · calibrated p 4e-5 ✓ | 30.5 EB05 30.0 · IC025 +4.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 23.6 · serious PRR 50.1 | NCT00291642: 1/116 (0.9%) on Cetirizine Allergy |
| Systemic lupus erythematosus | 7,067 | 174.2 170.1–178.3ROR 227.3 · calibrated p 1e-10 ✓ | 139.1 EB05 136.4 · IC025 +7.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 123.7 · serious PRR 105.2 · ♀ 100% (drug 79%) · 90% clinician | not reported in cached trials |
| Pemphigus | 6,940 | 893.6 863.8–924.4ROR 1,161.0 · calibrated p 4e-18 ✓ | 388.3 EB05 380.7 · IC025 +8.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 287.3 · ♀ 100% (drug 79%) · 90% clinician | not reported in cached trials |
| Off label use (used outside approved label) | 6,610 | 5.3 5.2–5.5ROR 6.6 · calibrated p 0.118 | 5.3 EB05 5.2 · IC025 +2.4 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 5.2 · serious PRR 6.6 | not reported in cached trials |
| Rash | 6,537 | 10.6 10.4–10.9ROR 13.3 · calibrated p 0.011 ✓ | 10.5 EB05 10.3 · IC025 +3.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 9.3 · serious PRR 16.8 | NCT00291642: 1/116 (0.9%) on Cetirizine Allergy |
| Glossodynia (burning tongue/mouth pain) | 6,419 | 281.6 274.1–289.2ROR 357.6 · calibrated p 2e-12 ✓ | 199.8 EB05 195.8 · IC025 +7.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 213.2 · ♀ 100% (drug 79%) · 92% clinician | not reported in cached trials |
| Swelling | 5,990 | 47.7 46.6–48.8ROR 59.3 · calibrated p 4e-6 ✓ | 44.7 EB05 43.7 · IC025 +5.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 36.3 · serious PRR 53.1 · 91% clinician | NCT00291642: 1/116 (0.9%) on Cetirizine Allergy |
| Hypersensitivity (allergic reaction) | 5,657 | 21.9 21.4–22.4ROR 26.7 · calibrated p 5e-4 ✓ | 21.3 EB05 20.8 · IC025 +4.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 21.3 · serious PRR 29.0 | not reported in cached trials |
| Hand deformity | 5,567 | 520.1 503.2–537.5ROR 637.8 · calibrated p 4e-15 ✓ | 296.0 EB05 289.5 · IC025 +8.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 237.4 · ♀ 100% (drug 79%) · 93% clinician | not reported in cached trials |
| Infusion related reaction (reaction during infusion) | 5,494 | 63.2 61.6–64.8ROR 77.0 · calibrated p 8e-7 ✓ | 57.9 EB05 56.6 · IC025 +5.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | age-adj. PRR 48.1 · serious PRR 53.6 · ♀ 99% (drug 79%) · 92% clinician | not reported in cached trials |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone Hydrochloride ↔ Drug Dependence.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Cetirizine Allergy?
In FDA FAERS, the most frequently co-reported reaction terms for Cetirizine Allergy are pain, fatigue, alopecia, rheumatoid arthritis, abdominal discomfort, systemic lupus erythematosus. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Cetirizine Allergy have an FDA boxed warning?
No. The FDA label retrieved for Cetirizine Allergy has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Cetirizine Allergy causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0cab7aa8-ded3-46f1-b801-2663cc9b0173, effective 20251003; matched on
openfda.generic_name.exact:"CETIRIZINE HYDROCHLORIDE ALLERGY") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,224 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
CETIRIZINE ALLERGY, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.